A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

This study is observing how well the Atectura inhaler (indacaterol/mometasone — a combination of a long-acting bronchodilator and a steroid) works for asthma patients in real-world clinical settings over 24 weeks. It is an observational study, meaning no new treatment is being tested — researchers are simply tracking outcomes of patients already prescribed this medication. **You may be eligible if...** - You are 12 years old or older and have been diagnosed with asthma by a doctor - You have been prescribed Atectura inhaler by your doctor as part of your regular care - You have consented to your data being collected for research purposes **You may NOT be eligible if...** - You have a known allergy to any ingredient in the inhaler - You have a hereditary problem with lactose digestion - You are currently having an acute asthma attack requiring a rescue inhaler - You are enrolled in another interventional clinical trial Talk to your doctor to see if this trial is right for you.